Evaluation of antibiotic resistance patterns of Klebsiella isolates: Five-year observation

Aim: Klebsiella spp. is a gram-negative rod, having many virulence factors such as capsule polysaccharides, adhesins, anddeterminants for iron acquisition. In this study, we aimed to determine the sub-species of Klebsiella spp. and their antibioticresistance profiles isolated from a tertiary hospital in a five-year period.Material and Methods: The antibiotic resistance profiles of Klebsiella spp. isolated from various clinical specimens of patientsbetween January 2014 and December 2018 were retrospectively reviewed.Results: In a total of 4506 isolates were investigated. Among those isolates, 2,254 were obtained from females and 2.252 were obtainedfrom males. The mean age of the patients was 47.71±29.56 while the median age was 56 years. On the other hand, 2.150 (47.7%)of the isolates were obtained from hospitalized patients, while 2356 (52.3%) were obtained from outpatients. Among those isolates,1.859 (41.3%) were ESBL positive and along with ESBL positive isolates, 802 were obtained from females and 1,057 were obtainedfrom males and ESBL positivity was significantly more common in males (p:0.001). Moreover, ESBL positivity was significantly morecommon in patients older than 18 years of age compared with the patients younger than 18 years of age. Ciprofloxacin resistancewas reaching 67.4% and Ertapenem resistance was as high as 39.1% in ESBL positive Klebsiella spp.Conclusion: In conclusion, ESBL positive and carbapenem resistant Klebsiella spp. strains are increasing. Multidrug resistantKlebsiella spp. strains may cause severe infections increasing mortality. In that aspect, the antibiotic resistance profile should beidentified clearly and further studies regarding the preventive measures should be planned.

PDF

___

1. Hennequin C, Robin F. Correlation between antimicrobial resistance and virulence in Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis 2016;35:333-41.
2. European Centre for Disease Prevention and Control (ECDC). Annual Epidemiological Report Reporting on 2011 Surveillance Data and 2012 Epidemic Intelligence Data. Stockholm: ECDC; 2013. p. 7
3. Agodi A, Auxilia F, Barchitta M, at al. Risk factors and outcomes of healthcare-associated infections within the Italian network SPIN-UTI. J Hosp Infect 2013;84:52-8.
4. Navonvenezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev 2017;41:252-75.
5. Agodi A, Barchitta M, Quattrocchi A, at al. Antibiotic trends of Klebsiella pneumoniae and Acinetobacter baumannii resistance indicators in an intensive care unit of Southern Italy, 2008-2013. Antimicrob Resist Infect Control 2015;4:43.
6. Boszczowski I, Salomão MC, Moura ML, at al. Rev Inst Med Trop Sao Paulo. 2019;61:e29. Multidrugresistant Klebsiella pneumoniae: genetic diversity, mechanisms of resistance to polymyxins and clinical outcomes in a tertiary teaching hospital in Brazil.
7. Gomez-Simmonds A, Nelson B, Eiras DP, at al. Combination regimens for treatment of carbapenemresistant Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2016;60:3601-7.
8. Menekşe Ş, Çağ Y, Işık ME, at al. The effect of colistin resistance and other predictors on fatality among patients with bloodstream infections due to Klebsiella pneumoniae in an OXA-48 dominant region. Int J Infect Dis 2019; pii: S1201-9712:30253-X.
9. EUCAST. EUCAST Clinical Breakpoint TableVersion 6.0, Valid From 2016-01-01. Basel: EUCAST, 2016. http://www.eucast.org/clinical_breakpoints/.
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-fourth informational supplement update. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA, 2014.
11. Cantas L, Shah SQ, Cavaco LM, , et al. A brief multidisciplinary review on antimicrobial resistance in medicine and its linkage to the global environmental microbiota. Front Microbiol 2013;4:96
12. Rojas LJ, Salim M, Cober E, et al. Colistin resistance in carbapenem-resistant Klebsiella pneumoniae: laboratory detection and impact on mortality. Clin Infect Dis 2016;64:711-8.
13. Zanichelli V, Huttner A, Harbarth S, et al. Swiss Centre for antibiotic resistance anresis. Antimicrobial resistance trends in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis urinary isolates from Switzerland: retrospective analysis of data from a national surveillance network over an 8-year period (2009-2016). Swiss Med Wkly 2019;149:20110.
14. Kuster SP, Hasse B, Huebner V, et al. Risks factors for infections with extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland. Infection 2010;38:33-40.
15. Gelband H, Miller-Petrie M, Pant S, et al. The State of the World’s Antibiotics. Washington, DC: Center for Disease Dynamics, Economics, Policy; 2015.
16. Legese MH, Weldearegay GM, Asrat D. Extendedspectrum beta-lactamase- and carbapenemaseproducing Enterobacteriaceae among Ethiopian children. Infect Drug Resist 2017;10:27-34.
17. Gajdács M, Ábrók M, Lázár A, et al. Comparative Epidemiology and Resistance Trends of Common Urinary Pathogens in a Tertiary-Care Hospital: A 10- Year Surveillance Study. Medicina (Kaunas) 20199;55.
18. Koksal E, Tulek N, Sonmezer MC, et al. Investigation of risk factors for community-acquired urinary tract infections caused by extended-spectrum betalactamase Escherichia coli and Klebsiella species. Investig Clin Urol 2019;60:46-53.
19. Nogueira Kda S, Paganini MC, Conte A, et al. Emergence of extended-spectrum beta-lactamase producing Enterobacter spp. in patients with bacteremia in a tertiary hospital in southern Brazil. Enferm Infecc Microbiol Clin 2014;32:87-92.
20. European Center for Disease Prevention and Control (ECDC). Antimicrobial resistance interactive database (EARS-Net). Stockholm: ECDC; [Accessed 07/12/2017]. Available from: http://atlas.ecdc. europa.eu/public/index.aspx.
21. Wang C, Yuan Z, Huang W, et al. Epidemiologic analysis and control strategy of Klebsiella pneumoniae infection in intensive care units in a teaching hospital of People’s Republic of China. Infect Drug Resist 2019;12:391-8.
22. Vega S, Dowzicky MJ. Antimicrobial susceptibility among gram-positive and gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance. Tria Ann Clin Microbiol Antimicrob 2017;16:50.
23. Li Y, Shen H, Zhu C, et al. Carbapenem-resistant klebsiella pneumoniae infections among icu admission patients in Central China: Prevalence and Prediction Model. Biomed Res Int 2019;2019:9767313.
24. World Health Organization. Antimicrobial resistance global report on surveillance. 2014. https://www.who. int/drugresistance/documents/surveillancereport/ en/(Erişim tarihi: Aralık 2018).
25. World Health Organization. Central asian and easterneuropean surveillance of anrimicrobial resistance(CAESAR), Annual report. 2018 http://www. euro.who.i n t / e n /health topics/disease prevention /antimicrobial-resistance/publications/2017/ centralasian-and-eastern-european-surveillance-of antimicrobial-resistance.-annual-report-2017-2018 (Erişim tarihi: Aralık 2018).
26. Neuner EA, Yeh JY, Hall GS, et al. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis 2011;69:357-62.
27. Rojas LJ, Salim M, Cober E, et al. Colistin resistance in carbapenem-resistant Klebsiella pneumoniae: Laboratory detection and impact on mortality. Clin Infect Dis 2017;64:711-8.
28. Arabacı Ç, Dal T, Başyiğit T, et al.Investigation of carbapenemase and mcr -1 genes in carbapenem -resistant Klebsiella pneumoniae isolates J Infect Dev Ctries 2019;13:504-9.